DRA contract ends & New advisory board member

Panion Animal Health AB's Director Regulatory Affairs, Niels-Erik Manniche, has decided to leave the company.

Niels-Erik Manniche's contract expires on the 31.st of March 2018, and he is available for the company in this period, if needed. Niels-Erik has been involved since the establishment of Panion and wishes us the best of luck for the future.

Anja Holm, CEO, takes over his responsibilities until the board has taken a new organizational decision.

Panion's advisory board has been expanded with Dr. Curtis W. Dewey from Cornell University, New York.
Dr. Curtis Dewey, DVM, MS, is a Diplomate of the American College of Veterinary Internal Medicine (Neurolo-gy), a Diplomate of the American College of Veterinary Surgeons, and an Associate Professor at the Section of Neurology/Neurosurgery in the veterinary faculty of Cornell University, Ithaca, New York, U.S.A.

Dr. Dewey's main research interests include seizure management, congenital disorders of the central nervous system, and complementary therapies for neurologic disease. Species focus is on dogs and cats.

Advisory board membership is a voluntary, independent, and non-remunerated position.

Anja E. H. Holm, CEO
+ 45-22 94 66 00
anja.holm@panion-animalhealth.com

Bolaget ska utveckla och kommersialisera genterapi för behandling av epilepsiliknande tillstånd hos hundar och andra djur, samt utveckla och kommersialisera andra veterinärmedicinska produkter och nya behandlingsformer som kan ge sjuka djur bättre livskvalitet.

Panion will develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, and other new animal health products and treatments that improve the quality of life for animals suffering from chronic diseases.

Nerladdningsbara filer

DRA contract ends & New advisory board member

Panion Animal Health AB's Director Regulatory Affairs, Niels-Erik Manniche, has decided to leave the company.

Niels-Erik Manniche's contract expires on the 31.st of March 2018, and he is available for the company in this period, if needed. Niels-Erik has been involved since the establishment of Panion and wishes us the best of luck for the future.

Anja Holm, CEO, takes over his responsibilities until the board has taken a new organizational decision.

Panion's advisory board has been expanded with Dr. Curtis W. Dewey from Cornell University, New York.
Dr. Curtis Dewey, DVM, MS, is a Diplomate of the American College of Veterinary Internal Medicine (Neurolo-gy), a Diplomate of the American College of Veterinary Surgeons, and an Associate Professor at the Section of Neurology/Neurosurgery in the veterinary faculty of Cornell University, Ithaca, New York, U.S.A.

Dr. Dewey's main research interests include seizure management, congenital disorders of the central nervous system, and complementary therapies for neurologic disease. Species focus is on dogs and cats.

Advisory board membership is a voluntary, independent, and non-remunerated position.

Anja E. H. Holm, CEO
+ 45-22 94 66 00
anja.holm@panion-animalhealth.com

Bolaget ska utveckla och kommersialisera genterapi för behandling av epilepsiliknande tillstånd hos hundar och andra djur, samt utveckla och kommersialisera andra veterinärmedicinska produkter och nya behandlingsformer som kan ge sjuka djur bättre livskvalitet.

Panion will develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, and other new animal health products and treatments that improve the quality of life for animals suffering from chronic diseases.

Nerladdningsbara filer

2017 Q4 report, October-December for Panion Animal Health

Period October-December

  • Net sales: kSEK 0 (0).
  • Operating profit: kSEK -854 (-643).
  • Earnings per share: SEK -0,32 (-0,09).
  • Liquidity at the end of the period: kSEK 2 124 (306)

Period January-December

  • Net sales: kSEK 0 (0).
  • Operating profit: kSEK -4 200 (-692).
  • Earnings per share: SEK -0,32 (-0,09).
  • Liquidity at the end of the period: kSEK 2 124 (306)

DRA contract ends & New advisory board member

Panion Animal Health AB's Director Regulatory Affairs, Niels-Erik Manniche, has decided to leave the company.


Panion enters into SEK 9,5 million financing and receives SEK 3 million in first tranche financing

Panion Animal Health AB (the "Company") has entered into a financing agreement with New York based Yorkville Advisors Global ("Yorkville") as the investment manager and on behalf of one or more of its investment funds has agreed to purchase up to SEK 9,000,000 of Convertible Notes of Panion Animal Health AB. In addition, Panion has entered into a financing agreement with Dividend Sweden who has agreed to purchase SEK 500,000 of convertible Notes of Panion Animal Health AB.


Panion's epilepsy product candidate for gene therapy in the dog: FDA has established an Investigational New Animal Drug (INAD) file.

Panion Animal Health AB ("Panion") has in Q4-17 requested the FDA to open an Investigational New Animal Drug application file to carry out the development of our new product for use in the dog. Panion plans to develop and gain approval for the use of CG-01-canine, a recombinant adeno-associated virus vector expressing neuropeptide Y and receptor peptide Y2 to treat drug refractory idiopathic epilepsy in the dog via intracranial injection.


New CFO in Panion, Sofia Josephson

Panion Animal Health AB has had a very satisfactory cooperation with our CFO Anni Acs, who excellently handled the business transition into the stock market, shares issue, and daily financial controlling. Anni has moved to a new job challenge and we wish her all the best.


Panion's epilepsy product classified as MUMS in EU for dogs and cats

Panion Animal Health AB has received the European Medicines Agency's acceptance of the classification as MUMS (Minor Use Minor Species) for our epilepsy product for both dogs and cats. The request for classification was submitted to the Committee for Medicinal Products for Veterinary Use (CVMP) in the European Medicines Agency (EMA) earlier in 2017 and has now been successfully evaluated. 


Panion's epilepsy drug candidate shows positive initial results in a long-term study by CombiGene

Panion Animal Health AB develops a new epilepsy medicine for dogs based on CombiGene's drug vector CG01. Initial results from CombiGene's long-term study in rats was released yesterday in a message, which is highly relevant for Panion's development of the product for epilepsy in dogs.



Panion at EMA's SME InfoDay

Panion has an active status as SME (Small and Medium-sized Enterprise) - at the European Medicines Agency (EMA), which gives access to a number of benefits, information sources, and financial incentives. CEO Anja Holm attended the SME InfoDay on Friday 17 November at the EMA's offices where agency officials together with scientific and regulatory experts from the European Network presented developments and were ready to meet and discuss with companies on an informal basis.


2017 Q3 report, July-September for Panion Animal Health

Period July-September 

  • Net sales: kSEK 0 (0)
  • Operating profit: kSEK -923 (-43)
  • Earnings per share: SEK -0,25 (-0,01)
  • Liquidity at the end of the period: kSEK 1 166 (541)

Period January-Sept 

  • Net sales: kSEK 0 (0).
  • Operating profit: kSEK -3 501 (-43)
  • Earnings per share: SEK -0,25 (-0,01)
  • Liquidity at the end of the period: kSEK 1 166 (541)

Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Sturegatan 32
114 36 Stockholm

08-692 21 90
Kontaktformulär

Kontakta oss

Vill du veta mer om beQuoted och våra tjänster så fyll i nedanstånde uppgifter och tryck skicka.

En av våra rådgivare kontaktar dig inom kort.

Namn: Telefon: E-postadress: Meddelande: